Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up on Analyst Upgrade

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) gapped up prior to trading on Thursday after Mizuho raised their price target on the stock from $205.00 to $250.00. The stock had previously closed at $128.60, but opened at $140.28. Mizuho currently has an outperform rating on the stock. Palvella Therapeutics shares last traded at $142.63, with a volume of 220,474 shares changing hands.

A number of other equities analysts have also commented on PVLA. Oppenheimer reissued an “outperform” rating and issued a $200.00 price target on shares of Palvella Therapeutics in a research report on Monday, December 15th. BTIG Research raised their target price on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday. Raymond James Financial reissued a “strong-buy” rating and set a $193.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Truist Financial set a $210.00 price target on Palvella Therapeutics in a research report on Tuesday. Finally, UBS Group reiterated a “buy” rating and issued a $143.00 price objective on shares of Palvella Therapeutics in a research note on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $176.44.

Insiders Place Their Bets

In related news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a document filed with the SEC, which is available through this link. 20.50% of the stock is currently owned by company insiders.

Key Palvella Therapeutics News

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Positive Phase 3 SELVA topline results for QTORIN™ 3.9% rapamycin (lead asset) — this is the primary catalyst driving buying interest because it materially de-risks the lead program and supports future commercialization prospects. Palvella Therapeutics Announces Positive Topline Results
• Positive Sentiment: Multiple analysts raised targets and forecasts after the clinical news — H.C. Wainwright boosted long‑range EPS forecasts and raised its price target to $255, while Mizuho, BTIG and Chardan also lifted targets (Mizuho to $250, BTIG to $215, Chardan to $210) — reinforcing buy-side momentum and analyst support. Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright Chardan Capital Boosts Palvella Therapeutics Price Target to $210
• Neutral Sentiment: Upsized public offering priced at $125.00 for 1.6M shares (with a 30‑day option for +240k) to raise ~ $200M to fund development and general corporate purposes — provides runway but introduces share supply and execution/closing risk; offering expected to close ~Feb 27. Palvella Therapeutics Announces Pricing of Upsized Public Offering
• Negative Sentiment: Short interest jumped ~22% in February to ~1.67M shares (~17.8% of float) with ~5.5 days-to-cover — indicates sizable bearish positions that can add selling pressure or create volatility (risk of short squeezes).
• Negative Sentiment: Insider selling activity and the company-led equity sale increase potential dilution concerns; investors should weigh near-term dilution against longer-term clinical upside. Palvella Therapeutics Announces $200 Million Upsized Public Offering

Institutional Trading of Palvella Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of PVLA. Archer Investment Corp acquired a new position in shares of Palvella Therapeutics in the third quarter valued at $28,000. Group One Trading LLC increased its holdings in Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after buying an additional 200 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Palvella Therapeutics in the 3rd quarter valued at $36,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Palvella Therapeutics during the 2nd quarter worth about $37,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after acquiring an additional 3,242 shares during the period. 40.11% of the stock is currently owned by institutional investors.

Palvella Therapeutics Stock Performance

The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -53.70 and a beta of -0.16. The firm’s 50-day moving average price is $92.78 and its two-hundred day moving average price is $78.86.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.